BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang Y, Zhao J, Qin Y, Yu Z, Zhang Y, Ning X, Sun S. The Specific Alteration of Gut Microbiota in Diabetic Kidney Diseases—A Systematic Review and Meta-Analysis. Front Immunol 2022;13:908219. [DOI: 10.3389/fimmu.2022.908219] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Shi R, Tao Y, Tang H, Wu C, Fei J, Ge H, Gu HF, Wu J. Abelmoschus Manihot ameliorates the levels of circulating metabolites in diabetic nephropathy by modulating gut microbiota in non-obese diabetes mice. Microb Biotechnol 2023;16:813-26. [PMID: 36583468 DOI: 10.1111/1751-7915.14200] [Reference Citation Analysis]
2 Mao ZH, Gao ZX, Liu DW, Liu ZS, Wu P. Gut microbiota and its metabolites - molecular mechanisms and management strategies in diabetic kidney disease. Front Immunol 2023;14:1124704. [PMID: 36742307 DOI: 10.3389/fimmu.2023.1124704] [Reference Citation Analysis]
3 Peters BA, Qi Q, Usyk M, Daviglus ML, Cai J, Franceschini N, Lash JP, Gellman MD, Yu B, Boerwinkle E, Knight R, Burk RD, Kaplan RC. Association of the gut microbiome with kidney function and damage in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). Gut Microbes 2023;15:2186685. [PMID: 36882941 DOI: 10.1080/19490976.2023.2186685] [Reference Citation Analysis]
4 Wang P, Guo R, Bai X, Cui W, Zhang Y, Li H, Shang J, Zhao Z. Sacubitril/Valsartan contributes to improving the diabetic kidney disease and regulating the gut microbiota in mice. Front Endocrinol (Lausanne) 2022;13:1034818. [PMID: 36589853 DOI: 10.3389/fendo.2022.1034818] [Reference Citation Analysis]
5 Hong J, Fu T, Liu W, Du Y, Min C, Lin D. Specific alterations of gut microbiota in diabetic microvascular complications: A systematic review and meta-analysis. Front Endocrinol (Lausanne) 2022;13:1053900. [PMID: 36545341 DOI: 10.3389/fendo.2022.1053900] [Reference Citation Analysis]
6 Nicholas SB, Mottl AK. Diabetic Kidney Disease. nephsap 2022;21:394-411. [DOI: 10.1681/nsap.00142022] [Reference Citation Analysis]
7 Chen Q, Ren D, Liu L, Xu J, Wu Y, Yu H, Liu M, Zhang Y, Wang T. Ginsenoside Compound K Ameliorates Development of Diabetic Kidney Disease through Inhibiting TLR4 Activation Induced by Microbially Produced Imidazole Propionate. Int J Mol Sci 2022;23. [PMID: 36361652 DOI: 10.3390/ijms232112863] [Reference Citation Analysis]
8 Han S, Chen M, Cheng P, Zhang Z, Lu Y, Xu Y, Wang Y. A systematic review and meta-analysis of gut microbiota in diabetic kidney disease: Comparisons with diabetes mellitus, non-diabetic kidney disease, and healthy individuals. Front Endocrinol 2022;13:1018093. [DOI: 10.3389/fendo.2022.1018093] [Reference Citation Analysis]